A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.

Like Comment
Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments.Concomitant chemosensitivity and genome-wide RNA profiles were performed on preclinical models (primary cell cultures and patient-derived xenografts) derived from patients with PDAC included in the PaCaOmics program (NCT01692873). The RNA-based stratification was tested in a monocentric cohort and validated in a multicentric cohort, both retrospectively collected from resected PDAC samples (67 and 368 patients, respectively). Forty-three (65%) and 203 (55%) patients received adjuvant gemcitabine in the monocentric and the multicentric cohorts, respectively. The relationship between predicted gemcitabine sensitivity and patients' overall survival (OS) and disease-free survival (DFS) were investigated.The GemPred RNA signature was derived from preclinical models, defining gemcitabine sensitive PDAC as GemPred+. Among the patients who received gemcitabine in the test and validation cohorts, the GemPred+ patients had a higher OS than GemPred- (p = 0.046 and p = 0.00216). In both cohorts, the GemPred stratification was not associated with OS among patients that did not receive gemcitabine. Among gemcitabine treated-patients, GemPred+ patients had significantly higher OS than the GemPred-: 91.3 months (95% CI: 61.2-not reached) vs 33 months (95% CI: 24-35.2); HR 0.403 (95% CI: 0.221-0.735, p = 0.00216). The interaction test for gemcitabine and GemPred+ stratification was significant (p = 0.0245). Multivariate analysis in the gemcitabine-treated population retained an independent predictive value.The RNA-based GemPred stratification predicts the benefit of adjuvant gemcitabine in PDAC patients.

View the full article @ Annals of oncology : official journal of the European Society for Medical Oncology

Get PDF with LibKey


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following